Determination of the phase 2 dose of AU-007, an AI-designed human monoclonal antibody that redirects IL-2 to T-effector cells

doi:10.1016/j.ejca.2024.114971

Return

Determination of the phase 2 dose of AU-007, an AI-designed human monoclonal antibody that redirects IL-2 to T-effector cells

2024-10-01

PRE

Ganessan Kichenadasse

DOI：10.1016/j.ejca.2024.114971

Original

Original request for help

Save

Abstract

Journal

European Journal of Cancer

IF:

7.1

Papers:

2.6W

Citations:

3.8W

Organization

Tennessee Oncology

Scholars:

672

Papers: 580

Citations: 918

Monash University

Scholars:

5.4W

Papers: 5.4W

Citations: 79

Huntsman Cancer Institute

Scholars:

2.1K

Papers: 1.6K

Citations: 6.1K

University of Utah

Scholars:

2.9W

Papers: 2.2W

Citations: 4.6W

University of Sydney

Scholars:

6.5W

Papers: 6.2W

Citations: 90

Sarah Cannon Research Institute

Scholars:

1.5K

Papers: 1.2K

Citations: 343

Utah System of Higher Education

Scholars:

4.5W

Papers: 3.9W

Citations: 161

austin research institute

Scholars:

3.9K

Papers: 2.8K

Citations: 6

florey institute of neuroscience & mental health

Scholars:

1.1W

Papers: 9.3K

Citations: 12

View more organizations